Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication

This study has been completed.
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by:
Cubist Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00101998
First received: January 18, 2005
Last updated: March 6, 2009
Last verified: March 2009
  Purpose

A multicenter study to evaluate the effectiveness and safety of multiple dosage regimens of an investigational drug for the treatment of constipation due to prescription pain medication in subjects with cancer pain. The study will require five visits over a five-week period.


Condition Intervention Phase
Constipation
Bowel Dysfunction
Drug: alvimopan
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects

Resource links provided by NLM:


Further study details as provided by Cubist Pharmaceuticals:

Primary Outcome Measures:
  • Change in weekly SCBM frequency. A SCBM is a spontaneous and complete bowel movement, which means a bowel movement that occurs with no laxative use in the prior 24 hours and leaves the subject with the feeling of complete evacuation of the rectum.

Secondary Outcome Measures:
  • Additional measures of Bowel movement (BM) frequency and symptoms, safety profile of the treatment regimens and any changes in pain intensity or opioid use.

Estimated Enrollment: 215
Study Start Date: October 2003
Intervention Details:
    Drug: alvimopan
    Other Name: alvimopan
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Subject is in any stage of cancer but has a minimum life expectancy of at least 3 months at the time of the Screening Visit.
  • Subject is taking opioid therapy for persistent cancer pain.
  • Subject meets the definition of opioid-induced bowel dysfunction as follows: Since starting opioid therapy, the subject has had decreased BM frequency and at least one of the following constipation symptoms [sensation of incomplete evacuation, difficulty in expelling stool (straining), hard stools (abnormal stool consistency)].
  • Subject understands the procedures, agrees to participate in the study, and has signed and dated the informed consent form prior to the initiation of any study-related activities, including discontinuation of pre-study laxative regimen or other prohibited medications.
  • Subject is able and willing to comply with a daily paper diary and is capable of completing paper questionnaires at study visits.

Exclusion criteria:

  • Subject is pregnant or lactating, or planning to become pregnant.
  • Subject is not ambulatory.
  • Subject has participated in another trial with an investigational drug (unapproved), device or procedure within 30 days of the Screening Visit.
  • Subject is unable to eat, drink, take/hold down oral medications.
  • Subject is taking opioids for the management of drug addiction.
  • Subject is unable or unwilling to discontinue the use of and/or refrain from using laxatives of all types and formulation at the Screening Visit and throughout the entire study.
  • Subject has severe constipation that has not been appropriately managed such that the subject is at immediate risk of developing serious complications of constipation. This would include a subject who has reported no bowel movement for 7 consecutive days prior to the Screening Visit.
  • Subject with gastrointestinal or pelvic disorders known to affect bowel transit, produce gastrointestinal (GI) obstruction, or contribute to bowel dysfunction.
  • Subject is currently taking vinca alkyloids or plans to take vinca alkyloids during the study.
  • Subject is currently undergoing abdominal radiation therapy and/or plans to undergo abdominal radiation therapy during the study.
  • Subject is HIV-infected, has active hepatitis (any subtype including ongoing chronic hepatitis B), or has ever been infected with hepatitis C.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00101998

  Hide Study Locations
Locations
United States, Arizona
GSK Investigational Site
Tucson, Arizona, United States, 85723
United States, Arkansas
GSK Investigational Site
Hot Springs, Arkansas, United States, 71913
United States, California
GSK Investigational Site
Duarte, California, United States, 91010
GSK Investigational Site
Fountain Valley, California, United States, 92708
GSK Investigational Site
Fresno, California, United States, 93720
GSK Investigational Site
La Verne, California, United States, 91750
GSK Investigational Site
Los Angeles, California, United States, 90057
GSK Investigational Site
Los Gatos, California, United States, 95032
GSK Investigational Site
Modesto, California, United States, 95355
GSK Investigational Site
Sacramento, California, United States, 95819
GSK Investigational Site
San Diego, California, United States, 92120
GSK Investigational Site
San Diego, California, United States, 92103
GSK Investigational Site
Santa Monica, California, United States, 90403
United States, Colorado
GSK Investigational Site
Denver, Colorado, United States, 80210
United States, District of Columbia
GSK Investigational Site
Washington, District of Columbia, United States, 20010
GSK Investigational Site
Washington, District of Columbia, United States, 20007
United States, Florida
GSK Investigational Site
Gainesville, Florida, United States, 32604
GSK Investigational Site
Inverness, Florida, United States, 34452
GSK Investigational Site
Lecanto, Florida, United States, 34461
GSK Investigational Site
Miami Shores, Florida, United States, 33138
GSK Investigational Site
New Port Richey, Florida, United States, 34653
GSK Investigational Site
New Port Richey, Florida, United States, 34652
GSK Investigational Site
Ocala, Florida, United States, 34474
GSK Investigational Site
Palm Harbor, Florida, United States, 34684
GSK Investigational Site
Stuart, Florida, United States, 34996
GSK Investigational Site
Tampa, Florida, United States, 33612-9497
GSK Investigational Site
Titusville, Florida, United States, 32796
United States, Georgia
GSK Investigational Site
Decatur, Georgia, United States, 30033
United States, Illinois
GSK Investigational Site
Chicago, Illinois, United States, 60610
United States, Iowa
GSK Investigational Site
West Des Moines, Iowa, United States, 50265
United States, Kansas
GSK Investigational Site
Hutchinson, Kansas, United States, 67502
United States, Maryland
GSK Investigational Site
Baltimore, Maryland, United States, 21218
GSK Investigational Site
Baltimore, Maryland, United States, 21229-5299
GSK Investigational Site
Baltimore, Maryland, United States, 21239
GSK Investigational Site
Bethesda, Maryland, United States, 20817
United States, Massachusetts
GSK Investigational Site
Boston, Massachusetts, United States, 02115
GSK Investigational Site
Boston, Massachusetts, United States, 02215
GSK Investigational Site
Worcester, Massachusetts, United States, 01608
United States, Michigan
GSK Investigational Site
Ann Arbor, Michigan, United States, 48109
GSK Investigational Site
Flint, Michigan, United States, 48503
United States, Minnesota
GSK Investigational Site
St. Louis Park, Minnesota, United States, 55426
United States, Missouri
GSK Investigational Site
Kansas City, Missouri, United States, 64114
GSK Investigational Site
St. Louis, Missouri, United States, 63141
United States, Nevada
GSK Investigational Site
Reno, Nevada, United States, 89502
United States, New Mexico
GSK Investigational Site
Albuquerque, New Mexico, United States, 87109
United States, New York
GSK Investigational Site
Bethpage, New York, United States, 11714
GSK Investigational Site
Huntington Station, New York, United States, 11746
GSK Investigational Site
Jamaica, New York, United States, 11432
United States, North Carolina
GSK Investigational Site
Chapel Hill, North Carolina, United States, 27599
GSK Investigational Site
Charlotte, North Carolina, United States, 28209
GSK Investigational Site
Durham, North Carolina, United States, 27710
GSK Investigational Site
Hendersonville, North Carolina, United States, 28793
GSK Investigational Site
Raleigh, North Carolina, United States, 27606
GSK Investigational Site
Winston-Salem, North Carolina, United States, 27103
United States, North Dakota
GSK Investigational Site
Bismarck, North Dakota, United States, 58501
GSK Investigational Site
Bismarck, North Dakota, United States, 58503
United States, Ohio
GSK Investigational Site
Canton, Ohio, United States, 44718
GSK Investigational Site
Middletown, Ohio, United States, 45042
United States, Oregon
GSK Investigational Site
Portland, Oregon, United States, 97225
United States, Tennessee
GSK Investigational Site
Nashville, Tennessee, United States, 37232
United States, Texas
GSK Investigational Site
Amarillo, Texas, United States, 79106
GSK Investigational Site
Houston, Texas, United States, 77030
GSK Investigational Site
Webster, Texas, United States, 77598
United States, Virginia
GSK Investigational Site
Norfolk, Virginia, United States, 23507
GSK Investigational Site
Portsmouth, Virginia, United States, 23704
GSK Investigational Site
Richmond, Virginia, United States, 23249
GSK Investigational Site
Richmond, Virginia, United States, 23298-5028
United States, Washington
GSK Investigational Site
Tacoma, Washington, United States, 98405
United States, Wisconsin
GSK Investigational Site
Milwaukee, Wisconsin, United States, 53215
Argentina
GSK Investigational Site
Capital Federal, Buenos Aires, Argentina, C1405CUB
GSK Investigational Site
Rosario, Santa Fe, Argentina, 2000
Australia, New South Wales
GSK Investigational Site
St Leonards, New South Wales, Australia, 2065
Australia, Queensland
GSK Investigational Site
Redcliffe, Queensland, Australia, 4020
GSK Investigational Site
South Brisbane, Queensland, Australia, 4101
Australia, South Australia
GSK Investigational Site
Daw Park, South Australia, Australia, 5041
Australia, Victoria
GSK Investigational Site
Malvern, Victoria, Australia, 3144
Canada, Manitoba
GSK Investigational Site
Winnipeg, Manitoba, Canada, R3A 1R9
Canada, Newfoundland and Labrador
GSK Investigational Site
Saint John's, Newfoundland and Labrador, Canada, A1B 3V6
Canada, Ontario
GSK Investigational Site
Kitchener, Ontario, Canada, N2G 1G3
GSK Investigational Site
London, Ontario, Canada, N6A 4L6
GSK Investigational Site
North Bay, Ontario, Canada, P1B 2H3
GSK Investigational Site
Oshawa, Ontario, Canada, L1G 2B9
GSK Investigational Site
Sudbury, Ontario, Canada, P3E 5J1
Canada, Quebec
GSK Investigational Site
Bonaventure, Quebec, Canada, G0C 1E0
GSK Investigational Site
Chandler, Quebec, Canada, G0C 1K0
GSK Investigational Site
Levis, Quebec, Canada, G6V 3Z1
GSK Investigational Site
Montreal, Quebec, Canada, H1T 2M4
GSK Investigational Site
Sherbrooke, Quebec, Canada, J1H 1Z1
Canada
GSK Investigational Site
Quebec, Canada, G1R 2J6
Czech Republic
GSK Investigational Site
Brno, Czech Republic, 625 00
GSK Investigational Site
Brno, Czech Republic, 656 91
GSK Investigational Site
Plzen, Czech Republic, 304 60
GSK Investigational Site
Praha 10, Czech Republic, 100 34
Finland
GSK Investigational Site
Helsinki, Finland, 00029
France
GSK Investigational Site
Bordeaux Cedex, France, 33076
GSK Investigational Site
Vandoeuvre-Les-Nancy, France, 54511
GSK Investigational Site
Villejuif Cedex, France, 94805
Germany
GSK Investigational Site
Goettingen, Niedersachsen, Germany, 37073
GSK Investigational Site
Goslar, Niedersachsen, Germany, 38642
Hong Kong
GSK Investigational Site
Kwun Tong, Hong Kong
GSK Investigational Site
Pokfulam, Hong Kong
GSK Investigational Site
Shatin, Hong Kong
Hungary
GSK Investigational Site
Budapest, Hungary, 1529
GSK Investigational Site
Budapest, Hungary, 1097
GSK Investigational Site
Miskolc, Hungary, 3529
GSK Investigational Site
Zalaegerszeg-Pozva, Hungary, 8900
India
GSK Investigational Site
Bangalore, India, 560 034
Italy
GSK Investigational Site
Caserta, Campania, Italy, 81100
GSK Investigational Site
Napoli, Campania, Italy, 80131
GSK Investigational Site
Forlì, Emilia-Romagna, Italy, 47100
GSK Investigational Site
Rimini, Emilia-Romagna, Italy, 47900
GSK Investigational Site
Genova, Liguria, Italy, 16132
GSK Investigational Site
Milano, Lombardia, Italy, 20127
GSK Investigational Site
Pavia, Lombardia, Italy, 27100
GSK Investigational Site
Busca (CN), Piemonte, Italy, 12022
GSK Investigational Site
Novara, Piemonte, Italy, 28100
GSK Investigational Site
Catania, Sicilia, Italy, 95124
GSK Investigational Site
Firenze, Toscana, Italy, 50139
Korea, Republic of
GSK Investigational Site
Seoul, Korea, Republic of, 152-703
GSK Investigational Site
Seoul, Korea, Republic of, 137-701
Netherlands
GSK Investigational Site
Leeuwarden, Netherlands, 8934 AD
New Zealand
GSK Investigational Site
Dunedin, New Zealand, 9001
GSK Investigational Site
Hastings, New Zealand, 4201
GSK Investigational Site
Wellington, New Zealand, 6002
Pakistan
GSK Investigational Site
Lahore, Pakistan, 54600
Peru
GSK Investigational Site
Lima, Peru, Lima 34
GSK Investigational Site
Lima, Peru, Lima 11
Philippines
GSK Investigational Site
Manila, Philippines, 1000
Poland
GSK Investigational Site
Bialystok, Poland, 15-540
GSK Investigational Site
Olsztyn, Poland, 10-228
GSK Investigational Site
Otwock, Poland, 05-400
GSK Investigational Site
Poznan, Poland, 60-569
Portugal
GSK Investigational Site
Lisboa, Portugal, 1800
GSK Investigational Site
Lisboa, Portugal, 1069-166 Lisboa
GSK Investigational Site
Lisboa, Portugal, 1070
Russian Federation
GSK Investigational Site
Moscow, Russian Federation, 117216
GSK Investigational Site
Moscow, Russian Federation, 127018
GSK Investigational Site
Moscow, Russian Federation, 119048
GSK Investigational Site
St'Petersburg, Russian Federation, 195247
South Africa
GSK Investigational Site
Durban, KwaZulu- Natal, South Africa, 4001
GSK Investigational Site
Groenkloof, Pretoria, South Africa
GSK Investigational Site
Houghton, Johannesburg, South Africa, 2000
GSK Investigational Site
Kenilworth, Cape Town, South Africa, 7745
Spain
GSK Investigational Site
Alcorcon, Spain, 28922
GSK Investigational Site
Barcelona, Spain, 08036
GSK Investigational Site
Barcelona, Spain, 08023
GSK Investigational Site
Cordoba, Spain, 14004
GSK Investigational Site
Granada, Spain, 18012
GSK Investigational Site
Jaén, Spain, 23007
GSK Investigational Site
Madrid, Spain, 28006
GSK Investigational Site
Sabadell / Barcelona, Spain
GSK Investigational Site
Serra / Valencia, Spain
GSK Investigational Site
Sevilla, Spain, 41014
GSK Investigational Site
Soria, Spain, 42002
GSK Investigational Site
Valencia, Spain, 46010
Taiwan
GSK Investigational Site
Taipei, Taiwan, 100
Thailand
GSK Investigational Site
Chiang Mai, Thailand, 50200
United Kingdom
GSK Investigational Site
London, United Kingdom, SW3 6JJ
GSK Investigational Site
Newcastle-upon-Tyne, United Kingdom, NE4 6BE
GSK Investigational Site
Nottingham, United Kingdom, NG5 1PB
GSK Investigational Site
Sheffield, United Kingdom, S10 2JF
GSK Investigational Site
Surrey, United Kingdom, SM2 5PT
Sponsors and Collaborators
Cubist Pharmaceuticals
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials, MD GlaxoSmithKline
  More Information

No publications provided

Responsible Party: Study Director, GSK
ClinicalTrials.gov Identifier: NCT00101998     History of Changes
Obsolete Identifiers: NCT00903513
Other Study ID Numbers: 767905/008
Study First Received: January 18, 2005
Last Updated: March 6, 2009
Health Authority: United States: Food and Drug Administration
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Cubist Pharmaceuticals:
OBD (Induced Bowel Dysfunction)
cancer pain
pain medication
constipation
bowel
bowel dysfunction

Additional relevant MeSH terms:
Constipation
Intestinal Diseases
Gastrointestinal Diseases
Signs and Symptoms, Digestive
Signs and Symptoms
Digestive System Diseases
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on April 15, 2014